• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Decisions, Decisions: Neoadjuvant Chemotherapy, Neoadjuvant Endocrine Therapy, or Primary Surgery?

作者信息

Cao Lifen, Montero Alberto J, Shenk Robert, Miller Megan E

机构信息

Department of Surgery, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

出版信息

Ann Surg Oncol. 2022 Dec;29(Suppl 3):562-563. doi: 10.1245/s10434-021-10621-x. Epub 2021 Aug 17.

DOI:10.1245/s10434-021-10621-x
PMID:34405294
Abstract
摘要

相似文献

1
ASO Author Reflections: Decisions, Decisions: Neoadjuvant Chemotherapy, Neoadjuvant Endocrine Therapy, or Primary Surgery?ASO作者反思：决策，决策：新辅助化疗、新辅助内分泌治疗还是原发手术？
Ann Surg Oncol. 2022 Dec;29(Suppl 3):562-563. doi: 10.1245/s10434-021-10621-x. Epub 2021 Aug 17.
2
ASO Author Reflections: Right Sizing Axillary Surgery in Patients treated with Neoadjuvant Endocrine Therapy.ASO作者反思：新辅助内分泌治疗患者腋窝手术的合理规模
Ann Surg Oncol. 2021 Dec;28(13):8740-8741. doi: 10.1245/s10434-021-10438-8. Epub 2021 Jul 16.
3
ASO Author Reflections: Nodal Downstaging and Conversion to Breast-Conserving Surgery Following Neoadjuvant Endocrine Therapy.ASO作者反思：新辅助内分泌治疗后腋窝降期及转换为保乳手术
Ann Surg Oncol. 2020 Dec;27(Suppl 3):693-694. doi: 10.1245/s10434-020-08971-z. Epub 2020 Aug 14.
4
ASO Author Reflections: Tailoring Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer.ASO作者反思：新辅助内分泌治疗后乳腺癌腋窝手术的个体化选择
Ann Surg Oncol. 2021 Mar;28(3):1368-1369. doi: 10.1245/s10434-020-09435-0. Epub 2021 Jan 2.
5
ASO Author Reflections: Neoadjuvant Endocrine Therapy: A Pill in Time Saves Nine.《美国外科医师学会（ASO）作者反思：新辅助内分泌治疗：及时服药，事半功倍》
Ann Surg Oncol. 2022 Mar;29(3):1692-1693. doi: 10.1245/s10434-021-11145-0. Epub 2022 Jan 6.
6
ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer.ASO作者反思：新辅助化疗转换：优化胰腺癌新辅助治疗顺序
Ann Surg Oncol. 2022 Mar;29(3):1592-1593. doi: 10.1245/s10434-021-11019-5. Epub 2021 Oct 27.
7
ASO Author Reflections: Elimination of Breast Cancer Surgery in Complete Responders After Neoadjuvant Chemotherapy: Imaging Perspective.ASO作者反思：新辅助化疗后完全缓解者的乳腺癌手术取消：影像学视角
Ann Surg Oncol. 2018 Dec;25(Suppl 3):628-629. doi: 10.1245/s10434-018-6780-3. Epub 2018 Sep 22.
8
ASO Author Reflections: Neoadjuvant Chemotherapy Does Not Affect Short-Term Outcomes After Breast Cancer Surgery.ASO作者反思：新辅助化疗不影响乳腺癌手术后的短期结局。
Ann Surg Oncol. 2022 May;29(5):3011-3012. doi: 10.1245/s10434-021-11277-3. Epub 2022 Jan 7.
9
ASO Author Reflections: Risk for Three-Course Neoadjuvant Chemotherapy in Advanced Esophageal Cancer.ASO作者反思：晚期食管癌三疗程新辅助化疗的风险
Ann Surg Oncol. 2023 Sep;30(9):5908-5909. doi: 10.1245/s10434-023-13558-5. Epub 2023 Jun 8.
10
ASO Author Reflections: The Role of Imaging Modalities in Omitting Surgery in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.ASO作者反思：影像模态在接受新辅助化疗的乳腺癌患者中避免手术的作用。
Ann Surg Oncol. 2021 Nov;28(12):7430-7431. doi: 10.1245/s10434-021-10178-9. Epub 2021 May 22.

本文引用的文献

1
Axillary Response in Patients Undergoing Neoadjuvant Endocrine Treatment for Node-Positive Breast Cancer: Systematic Literature Review and NCDB Analysis.接受新辅助内分泌治疗的淋巴结阳性乳腺癌患者的腋窝反应：系统文献回顾和 NCDB 分析。
Ann Surg Oncol. 2020 Nov;27(12):4669-4677. doi: 10.1245/s10434-020-08905-9. Epub 2020 Sep 9.
2
How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?新辅助内分泌治疗（NET）在降期腋窝和实现保乳手术方面的效果如何？
Ann Surg Oncol. 2020 Nov;27(12):4702-4710. doi: 10.1245/s10434-020-08888-7. Epub 2020 Aug 24.
3
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
随机Ⅱ期新辅助对比来曲唑、阿那曲唑和依西美坦治疗绝经后雌激素受体阳性 2-3 期乳腺癌患者：临床和生物标志物结果以及基于 PAM50 的基线内在亚型的预测价值——ACOSOG Z1031。
J Clin Oncol. 2011 Jun 10;29(17):2342-9. doi: 10.1200/JCO.2010.31.6950. Epub 2011 May 9.
4
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.乳腺癌新辅助与辅助全身治疗的荟萃分析
J Natl Cancer Inst. 2005 Feb 2;97(3):188-94. doi: 10.1093/jnci/dji021.